Previous 10 | Next 10 |
As the health crisis spirals into a financial one, the liquidation and panic selling have indiscriminately hit sectors across the board. The biotechs were no exception, with the S&P Biotech ETF ( XBI ) plummeting -20% on the year in tandem with the S&P 500 (SPY). Source: WingCapital...
Stating the obvious, Baird analysts have created three lists of healthcare companies that may be worth a look considering their attractive valuations or relatively strong capitalizations amid the COVID-19 selloff. More news on: IDEAYA Biosciences, Inc., Surface Oncology, Inc., Jounce Thera...
ACADIA Pharmaceuticals (NASDAQ: ACAD ) initiated with Buy rating and $69 (55% upside) price target at Citigroup. More news on: ACADIA Pharmaceuticals Inc., Alector, Inc., GW Pharmaceuticals plc, Healthcare stocks news, , Stocks on the move, Read more ...
There are a lot of promising stocks out there for investors to choose from. However, if you're looking for companies with the most growth potential, the world of small-cap stocks is one of the best places to look. In particular, biotech stocks are very well known for having tremendous upside ...
The investment research arm of Barclays (NYSE: BCS ,LSE:BARC) is not worried about drug pricing concerns in the US; instead, it has a positive outlook for the country’s biopharma industry. On Wednesday (February 26), Barclays Capital launched its coverage of the US biopharma space w...
SAN DIEGO , Feb. 25, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Cowen 40 th Annual Health Care Conference at 12:00 p.m. Eastern Time on Tuesday , Mar. 3, 2020, in Boston . Kevin Gorman , Chief Executive Officer, will present at the conference....
Introduction Xenon Pharmaceuticals ( XENE ), a Canadian biotech, is quietly developing a pipeline of promising orphan/CNS assets. 2020 is likely to see two phase 2 readouts as well as two trial initiations (one pivotal). XEN1101, a novel Kv7 Potassium Channel Modulator, is being trialed in...
AbbVie (NYSE: ABBV ) initiated with Buy rating and $96 (11% upside) price target at Mizuho Securities. Shares up a fraction premarket. More news on: AbbVie Inc., Alkermes plc, BioLife Solutions, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
No one can complain about Neurocrine Biosciences ' (NASDAQ: NBIX) stock performance in 2019. The biotech's shares skyrocketed more than 50% last year. So far in 2020, though, Neurocrine hasn't given investors many reasons to cheer. Until now. Neurocrine announced its 2019 fourth-quarter...
Image source: The Motley Fool. Neurocrine Biosciences Inc (NASDAQ: NBIX) Q4 2019 Earnings Call Feb 4, 2020 , 4:30 p.m. ET Operator Continue reading
News, Short Squeeze, Breakout and More Instantly...
Neurocrine Biosciences Inc. Company Name:
NBIX Stock Symbol:
NASDAQ Market:
Neurocrine Biosciences Inc. Website:
A look at the top 10 most actives in the United States Redhill Biopharma Ltd. (RDHL) rose 41.5% to $0.5434 on volume of 82,457,301 shares FSD Pharma Inc. (HUGE) rose 9.8% to $0.1109 on volume of 60,485,300 shares NVIDIA Corporation (NVDA) rose 2.3% to $119.75 on volume of 54,756,180 shares ...
Neurocrine Biosciences Reports Second Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance PR Newswire INGREZZA ® (valbenazine) Second Quarter Net Product Sales of $580 Million Representing 32% Year-Over-Year Growth INGREZZA ...
Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing PR Newswire SAN DIEGO , July 18, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX...